Literature DB >> 19582313

HIV infection and psychiatric illness.

B Owe-Larsson1, L Säll, E Salamon, C Allgulander.   

Abstract

OBJECTIVE: To review the clinical features and current knowledge on the treatment of psychiatric symptoms and disorders in patients with human immunodeficiency virus (HIV) infection.
METHOD: We searched the PubMed database combining HIV/AIDS with different keywords for psychiatric diagnoses and symptoms (e.g. depression, mania, anxiety, psychosis, dementia, substance abuse) and for psychopharmacological treatment. The years covered by these searches included 1980 to 2008.
RESULTS: Patients with HIV infection are at an increased risk of psychiatric illness. Major depressive disorder and subsyndromal depressive symptoms, as well as anxiety disorder and substance abuse are more prevalent among HIV infected individuals than among the general population. HIV-associated neurocognitive disorders (HAND) are common among HIV patients, and HIV-associated dementia (HAD) is a serious condition during the acquired immune deficiency syndrome (AIDS) stage of HIV disease. Secondary mania and psychosis might be the first clinical symptom of HIV dementia. The introduction of highly active anti-retroviral therapy (HAART) has resulted in significant decreases in morbidity and mortality for HIV infected patients. HAART has also decreased the incidence of HAD, but does not give complete protection from this condition. The utility of psychotropic medications in HIV patients has not been studied sufficiently as a basis for guidelines, and more controlled trials are needed.
CONCLUSION: Psychiatric illness is common in HIV infected individuals, and underlines the importance for screening not only for cognitive impairment but also for co morbid mental disease in HIV-positive patients. Further studies of the neuropsychiatric complications during HIV disease and the use of psychotropics under these circumstances are clearly needed. A better understanding of the pathogenesis of HAD is essential to identify additional therapeutic strategies for prevention and treatment of this neurodegenerative disease. Studies are also needed for optimizing effective utilization of antiretrovirals into the CNS. Mania and psychosis secondary to HAD may be used as an indicator to initiate HAART, irrespective of CD4 count. Further research on the utility of HAART in the treatment of such acute neuropsychiatric symptoms associated with HIV infection should be initiated.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19582313     DOI: 10.4314/ajpsy.v12i2.43729

Source DB:  PubMed          Journal:  Afr J Psychiatry (Johannesbg)


  52 in total

1.  The validity of the Patient Health Questionnaire for screening depression in chronic care patients in primary health care in South Africa.

Authors:  Arvin Bhana; Sujit D Rathod; One Selohilwe; Tasneem Kathree; Inge Petersen
Journal:  BMC Psychiatry       Date:  2015-05-23       Impact factor: 3.630

2.  Psychiatric morbidity in HIV-infected male prisoners.

Authors:  Eugene Yu-Chang Peng; Ming-Been Lee; Donald Edward Morisky; Ching-Ying Yeh; David Farabee; Yu-Ching Lan; Yi-Ming Arthur Chen; Shu-Yu Lyu
Journal:  J Formos Med Assoc       Date:  2010-03       Impact factor: 3.282

Review 3.  Mental health of HIV-seropositive women during pregnancy and postpartum period: a comprehensive literature review.

Authors:  Suad Kapetanovic; Priscilla Dass-Brailsford; Diana Nora; Nicholas Talisman
Journal:  AIDS Behav       Date:  2014-06

Review 4.  Beyond one pill, once daily: current challenges of antiretroviral therapy management in the United States.

Authors:  Mary Clare Masters; Karen M Krueger; Janna L Williams; Lindsay Morrison; Susan E Cohn
Journal:  Expert Rev Clin Pharmacol       Date:  2019-12       Impact factor: 5.045

5.  Gender Differences in Psychosocial Factors Associated with HIV Viral Suppression Among African-American Injection Drug Users.

Authors:  Allysha C Robinson; Amy R Knowlton
Journal:  AIDS Behav       Date:  2016-02

6.  Poor CD4 count is a predictor of untreated depression in human immunodeficiency virus-positive African-Americans.

Authors:  Sasraku Amanor-Boadu; MariaMananita S Hipolito; Narayan Rai; Charlee K McLean; Kyla Flanagan; Flora T Hamilton; Valerie Oji; Sharon F Lambert; Huynh Nhu Le; Suad Kapetanovic; Evaristus A Nwulia
Journal:  World J Psychiatry       Date:  2016-03-22

Review 7.  HIV, antiretroviral therapies, and the brain.

Authors:  Kevin J Liner; Michelle J Ro; Kevin R Robertson
Journal:  Curr HIV/AIDS Rep       Date:  2010-05       Impact factor: 5.071

8.  Single-nucleotide polymorphisms in TrkB and risk for depression: findings from the women's interagency HIV study.

Authors:  Valeriya Avdoshina; Italo Mocchetti; Chenglong Liu; Mary A Young; Kathryn Anastos; Mardge Cohen; Howard Crystal; Celeste L Pearce; Elizabeth T Golub; Rochelle E Tractenberg
Journal:  J Acquir Immune Defic Syndr       Date:  2013-10-01       Impact factor: 3.731

9.  Diagnostic validity of the Patient Health Questionnaire-2 (PHQ-2) among Ethiopian adults.

Authors:  Bizu Gelaye; Ijala Wilson; Hanna Y Berhane; Negussie Deyessa; Yonas Bahretibeb; Dawit Wondimagegn; Teshome Shibre Kelkile; Yemane Berhane; Jesse R Fann; Michelle A Williams
Journal:  Compr Psychiatry       Date:  2016-07-30       Impact factor: 3.735

10.  Culturally Sensitive Approaches to Identification and Treatment of Depression among HIV Infected African American Adults: A Qualitative Study of Primary Care Providers' Perspectives.

Authors:  Huynh-Nhu Le; Maria Mananita S Hipolito; Sharon Lambert; Flora Terrell-Hamilton; Narayan Rai; Charlee McLean; Suad Kapetanovic; Evaristus Nwulia
Journal:  J Depress Anxiety       Date:  2016-04-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.